In Brief: Eclipse Surgical Technologies
This article was originally published in The Gray Sheet
Eclipse Surgical Technologies: Inks deal with Saluggia, Italy-based Sorin Biomedica Cardio, S.p.A. under which Sorin agrees to purchase at least 30 of Eclipse's laser-based transmyocardial revascularization (TMR) systems by Dec. 31, 1997, for marketing outside the U.S. Eclipse currently is engaged in clinical trials for its TMR system to treat patients with severe angina ("The Gray Sheet" Feb. 12, p. 12)...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.